Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
BLFS

BioLife Solutions Inc

BLFS

13.68USD-0.18 (-1.30%)Delayed as of 05 Dec 2023, 10:02 am
Watchlist

Market Summary

USD13.68-0.18
Delayedas of 05 Dec 2023, 10:02 am
-1.30%

BLFS Alerts

  • 1 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

BLFS Stock Price

View Fullscreen

BLFS RSI Chart

BLFS Valuation

Market Cap

607.5M

Price/Earnings (Trailing)

-5.9

Price/Sales (Trailing)

3.92

EV/EBITDA

-6.28

Price/Free Cashflow

-36.16

BLFS Price/Sales (Trailing)

BLFS Profitability

EBT Margin

-52.20%

Return on Equity

-23.88%

Return on Assets

-19.41%

Free Cashflow Yield

-2.77%

BLFS Fundamentals

BLFS Revenue

Revenue (TTM)

154.8M

Revenue Y/Y

-18.21%

Revenue Q/Q

-15.64%

BLFS Earnings

Earnings (TTM)

-102.9M

Earnings Y/Y

-192.58%

Earnings Q/Q

-185.64%

Price Action

52 Week Range

10.4826.89
(Low)(High)

Last 7 days

2.9%

Last 30 days

21.1%

Last 90 days

6.4%

Trailing 12 Months

-36.9%

How does BLFS drawdown profile look like?

BLFS Financial Health

Current Ratio

3.04

BLFS Investor Care

Shares Dilution (1Y)

2.64%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023163.2M162.2M154.8M0
2022138.5M147.9M154.8M161.8M
202152.8M74.1M96.6M119.2M
202033.8M37.0M41.7M48.1M
201921.7M23.2M24.5M27.4M
201812.5M15.1M17.4M19.7M
20178.7M9.3M10.1M11.0M
20166.8M7.3M7.8M8.2M
20155.6M5.9M6.3M6.4M
20149.6M8.5M7.6M6.2M
20135.4M6.7M7.2M8.2M
20123.0M3.5M4.4M5.7M
20112.3M2.4M2.6M2.8M
20100002.1M

Latest Insider Trading transactions for BLFS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 13, 2023
berard todd
sold
-1,055
10.77
-98.00
chief marketing officer
Nov 13, 2023
foster karen a.
sold
-1,227
10.77
-114
chief quality officer
Nov 13, 2023
phillips geraint
sold
-1,183
10.66
-111
svp, global operations
Nov 13, 2023
wichterman troy
sold
-1,034
10.66
-97.00
chief financial officer
Nov 13, 2023
aebersold sarah
sold
-818
10.77
-76.00
chief human resources officer
Nov 13, 2023
mathew aby j.
sold
-1,421
10.77
-132
evp & chief scientific officer
Nov 05, 2023
mathew aby j.
acquired
-
-
924
evp & chief scientific officer
Nov 05, 2023
foster karen a.
acquired
-
-
299
chief quality officer
Nov 05, 2023
phillips geraint
acquired
-
-
262
svp, global operations
Nov 05, 2023
wichterman troy
acquired
-
-
333
chief financial officer

1–10 of 50

Which funds bought or sold BLFS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-73.73
-1,396,590
274,349
-%
Nov 22, 2023
Public Sector Pension Investment Board
reduced
-31.18
-777,305
586,442
-%
Nov 22, 2023
KBC Group NV
unchanged
-
-
57,000
-%
Nov 21, 2023
COMERICA BANK
new
-
258,722
258,722
-%
Nov 21, 2023
Spears Abacus Advisors LLC
reduced
-5.03
-258,793
377,731
0.03%
Nov 15, 2023
MORGAN STANLEY
reduced
-3.24
-3,426,670
5,240,770
-%
Nov 15, 2023
Tudor Investment Corp Et Al
new
-
1,035,050
1,035,050
0.01%
Nov 15, 2023
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-222,304
-
-%
Nov 15, 2023
Baker Avenue Asset Management, LP
unchanged
-
-4,924
8,203
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
2.14
-110,613
195,163
-%

1–10 of 47

Latest Funds Activity

Are funds buying BLFS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BLFS
No. of Funds

Schedule 13G FIlings of BioLife Solutions Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Oct 24, 2023
casdin capital, llc
19.5%
8,707,165
SC 13D/A
Sep 26, 2023
integrated core strategies (us) llc
5.5%
2,406,913
SC 13G
Feb 09, 2023
vanguard group inc
5.77%
2,466,931
SC 13G/A
Jan 26, 2023
blackrock inc.
12.8%
5,477,126
SC 13G/A
Jan 20, 2023
blackrock inc.
12.8%
5,477,126
SC 13G/A
Jan 11, 2023
millennium management llc
1.6%
670,202
SC 13G/A
Jul 08, 2022
blackrock inc.
11.5%
4,893,203
SC 13G
Jun 22, 2022
millennium management llc
5.1%
2,166,344
SC 13G
Feb 09, 2022
vanguard group inc
5.16%
2,147,258
SC 13G
Feb 01, 2022
blackrock inc.
8.8%
3,655,057
SC 13G/A

Recent SEC filings of BioLife Solutions Inc

View All Filings
Date Filed Form Type Document
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Nov 30, 2023
S-3/A
S-3/A
Nov 17, 2023
S-3
S-3
Nov 17, 2023
S-3
S-3
Nov 15, 2023
4
Insider Trading

BLFS Fair Value

Loading...

Peers (Alternatives to BioLife Solutions Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.0B
40.0B
9.73% -2.70%
35.46
4.58
-11.26% -34.57%
71.3B
19.4B
-8.25% -5.16%
44.09
3.79
2.66% -16.58%
18.7B
15.0B
8.63% -30.19%
7.2
1.24
3.01% 209.09%
16.8B
3.8B
11.22% 10.68%
46.36
4.42
-1.48% -28.97%
MID-CAP
9.0B
12.7B
11.09% -16.77%
20.24
0.71
0.68% -30.25%
9.0B
2.7B
7.31% -26.28%
-56.42
3.3
-3.01% 97.36%
8.4B
3.4B
2.45% 18.85%
30.02
2.45
3.13% 18.17%
6.9B
3.9B
12.08% 3.35%
-31.81
1.76
-2.62% 73.28%
2.9B
342.6M
6.85% -17.46%
-245.59
8.59
42.19% 84.14%
2.5B
6.6B
-16.25% -11.02%
12.27
0.37
2.61% 0.62%
SMALL-CAP
1.2B
3.1B
8.50% -59.80%
-2.91
0.4
7.95% -550.16%
333.0M
163.3M
7.72% -27.92%
-13.55
2.04
7.14% -56.09%
272.3M
335.9M
-0.73% -44.59%
42.24
0.81
4.71% 116.39%
74.8M
50.3M
-17.56% 18.68%
-4.94
1.49
3.23% 20.81%
5.1M
3.8M
9.63% -51.71%
-0.44
1.35
17.30% 10.67%

BioLife Solutions Inc News

Latest updates
Knox Daily04 Dec 202311:55 pm15 hours ago
Seeking Alpha29 Nov 202308:06 pm5 days ago
Yahoo Finance15 Nov 202308:00 am20 days ago
Yahoo Finance01 Nov 202307:00 am34 days ago
Investing.com UK24 Oct 202307:00 am42 days ago
PR Newswire19 Oct 202307:00 am47 days ago
Defense World13 Oct 202309:00 am53 days ago
Yahoo Finance09 Oct 202307:00 am57 days ago
Simply Wall St21 Sep 202307:00 am2 months ago
Yahoo Finance08 Aug 202307:00 am3 months ago
Yahoo Finance03 Aug 202307:00 am4 months ago
PR Newswire14 Jun 202307:00 am5 months ago
PR Newswire06 Jun 202307:00 am6 months ago

Financials for BioLife Solutions Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-15.6%33,328,00039,508,00037,703,00044,259,00040,747,00040,533,00036,220,00037,305,00033,800,00031,204,00016,847,00014,726,00011,279,0009,920,00012,162,0008,296,0006,604,0006,701,0005,770,0005,456,0005,293,000
Gross Profit-----------------4,520,0004,743,0004,123,0003,746,0003,687,000
Costs and Expenses13.4%62,111,00054,788,00051,308,00094,182,50052,152,000117,096,00044,187,00055,770,00044,959,00035,759,00017,828,00020,135,00012,525,0009,876,00011,792,0009,057,0007,376,0005,954,0005,204,000--
Operating Expenses-----------------7,376,0005,954,0005,204,000-1,803,5004,098,000
  S&GA Expenses14.8%7,256,0006,318,0006,471,0005,987,0005,277,0005,415,0004,891,0004,778,0004,065,0003,142,0002,021,0001,883,0001,588,0001,366,0001,576,0001,669,0001,250,000945,000837,000637,000725,000
  R&D Expenses11.6%5,402,0004,840,0004,152,0004,164,0003,425,0003,428,0003,781,0003,570,5003,219,0003,045,0001,987,0001,855,0001,725,0001,477,0001,663,0001,086,0001,032,000691,000359,000315,000312,000
EBITDA Margin100.0%--0.47-0.88-0.85-0.67-0.67-0.21-0.19-0.13-0.13-0.410.030.190.521.16-0.09-----
Interest Expenses4.8%459,000438,000497,000356,000109,00030,00091,000452,000----4,0003,000-1,000-5,0001,0001,0003,0001,5001,000
Income Taxes2200.0%115,0005,00092,00045,997,446,500-599,000-3,739,000-599,000-2,578,000-4,988,000-12,552,000--3,264,000----1,541,000-----
Earnings Before Taxes-184.6%-29,017,000-10,194,000-13,622,000-49,973,500-10,556,000-76,617,000-8,020,000-18,323,000-4,909,000-4,676,000-1,118,000-6,076,000-1,133,000-16,380,00022,308,0001,442,00010,269,0004,252,000-19,161,000-27,378,0001,231,000
EBT Margin100.0%--0.52-0.92-0.90-0.72-0.72-0.25-0.23-0.17-0.17-0.46-0.010.150.481.13-0.12-----
Net Income-185.6%-29,132,000-10,199,000-13,714,000-49,888,500-9,957,000-72,878,000-7,421,000-15,745,00079,0007,876,000-1,118,000-2,812,000-1,133,000-16,380,00022,308,0002,983,00010,269,0004,252,000-19,161,00020,933,000-24,465,000
Net Income Margin100.0%--0.52-0.90-0.86-0.67-0.64-0.10-0.060.050.05-0.390.060.190.491.05-0.06-----
Free Cashflow100.0%--8,327,000-6,007,0003,409,000-950,000-11,952,000-9,380,000-2,340,000-329,000-10,409,000100,000666,000-621,0004,098,000541,000-1,322,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.1%41143344645048847154455455952124023519611495.0093.0084.0051.0048.0045.0046.00
  Current Assets-2.9%11712013313813611811912613112711711512846.0026.0024.0032.0029.0039.0038.0038.00
    Cash Equivalents-10.0%19.0021.0019.0019.0027.0024.0059.0070.0075.0076.0089.0090.0094.0030.006.006.0021.0020.0032.0031.0032.00
  Inventory10.7%43.0039.0041.0035.0034.0033.0030.0028.0030.0026.0012.0012.0011.0011.0011.0011.006.005.004.004.003.00
  Net PPE-17.9%21.0026.0026.0024.0022.0019.0018.0018.0017.0016.0011.0010.005.005.005.006.002.001.001.001.001.00
  Goodwill0%22522522522522522522522522419658.0058.0025.0034.0034.0034.0028.0010.0010.00--
Liabilities-2.4%79.0081.0088.0086.0079.0061.0068.0076.0070.0069.0031.0030.009.008.0027.0049.0049.0049.0052.0031.0053.00
  Current Liabilities7.7%43.0040.0047.0045.0037.0036.0038.0043.0036.0031.0016.0016.008.007.0025.008.005.003.003.002.002.00
    LT Debt, Current160.2%5.002.001.002.002.001.001.001.002.003.00-1.00---------
    LT Debt, Non Current-11.2%21.0024.0024.0024.0024.006.006.006.006.005.00-1.00---------
Shareholder's Equity-5.7%33235235836440841047647848945220920418710668.0043.0035.002.0044.0015.0044.00
  Retained Earnings-10.8%-299-270-260-246-194-187-114-107-90.55-90.63-98.50-97.38-95.26-94.12-77.74100-103-113-117-98.39-119
  Additional Paid-In Capital1.5%633623619612604598591585580543307303282200145143138115114113113
Accumulated Depreciation----------------3.002.002.002.002.002.00
Shares Outstanding0.9%44.0043.0043.0043.0043.0042.0042.0042.0041.0038.0033.0033.0032.0023.0021.0019.0020.0019.0019.0019.0018.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations43.3%-4,379-7,718-2,7127,8571,496-9,917-7,924-7742,083-7,7221,8202,257-5024,203687-1,0031,137-67.001,146585808
  Share Based Compensation33.0%9,1176,8577,3637,6636,2995,9735,3995,0654,8672,5191,5052,1631,5601,1451,113864830818531388383
Cashflow From Investing-82.1%1,6629,2922,926-14,894-15,883-25,070-2,270-2,542-2,007-4,216-4,427-22,057-975-456-1,227-14,021-292-12,549-156-161-5,278
Cashflow From Financing-13.6%608704-562-62517,411-289-181-2,105-1,058-8311,2161,27280,58219,732492267743409177-2,14822,683

BLFS Income Statement

2023-09-30
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total product, rental, and service revenue$ 33,328$ 40,747$ 110,538$ 117,500
Costs and operating expenses:    
General and administrative12,51311,91642,75735,098
Sales and marketing7,2565,27820,04515,601
Research and development5,4023,42514,39710,634
Asset impairment charges15,485015,48569,900
Intangible asset amortization1,3562,5134,2668,236
Change in fair value of contingent consideration(1,580)2,346(1,778)(3,348)
Total operating expenses62,11152,487168,208213,770
Operating loss(28,783)(11,740)(57,670)(96,270)
Other (expense) income:    
Change in fair value of investments06970697
Gain on settlement of Global Cooling escrow005,1150
Interest expense, net(476)(15)(1,305)(250)
Other income2421421,027270
Total other (expense) income, net(234)8244,837717
Loss before income tax (expense) benefit(29,017)(10,916)(52,833)(95,553)
Income tax (expense) benefit(115)599(212)4,937
Net loss(29,132)(10,317)(53,045)(90,616)
Net loss attributable to common shareholders:    
Net loss attributable to common shareholders, basic(29,132)(10,317)(53,045)(90,616)
Net loss attributable to common shareholders, diluted$ (29,132)$ (10,317)$ (53,045)$ (90,616)
Net loss per share attributable to common shareholders:    
Net loss per share attributable to common shareholders, basic (in dollars per share)$ (0.67)$ (0.24)$ (1.22)$ (2.14)
Net loss per share attributable to common shareholders, diluted (in dollars per share)$ (0.67)$ (0.24)$ (1.22)$ (2.14)
Weighted average shares used to compute loss per share attributable to common shareholders:    
Weighted average shares used to compute loss per share attributable to common shareholders, basic (in shares)43,570,43842,647,96743,348,41242,376,392
Weighted average shares used to compute loss per share attributable to common shareholders, diluted (in shares)43,570,43842,647,96743,348,41242,376,392
Product revenue    
Total product, rental, and service revenue$ 26,891$ 33,668$ 91,520$ 98,227
Costs and operating expenses:    
Cost of goods and services sold (exclusive of intangible assets amortization)16,66521,87657,02263,377
Service revenue    
Total product, rental, and service revenue4,3784,33013,04311,117
Costs and operating expenses:    
Cost of goods and services sold (exclusive of intangible assets amortization)3,9453,25311,8738,810
Rental revenue    
Total product, rental, and service revenue2,0592,7495,9758,156
Costs and operating expenses:    
Cost of goods and services sold (exclusive of intangible assets amortization)$ 1,069$ 1,880$ 4,141$ 5,462

BLFS Balance Sheet

2023-09-30
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 19,235$ 19,442
Restricted cash3131
Available-for-sale securities, current portion21,79443,260
Accounts receivable, trade, net of allowance for credit losses of $1,244 and $739 as of September 30, 2023 and December 31, 2022, respectively24,55633,936
Inventories43,35434,904
Prepaid expenses and other current assets7,8546,879
Total current assets116,824138,452
Assets held for rent, net7,2099,064
Property and equipment, net20,99823,638
Operating lease right-of-use assets, net12,65115,292
Financing lease right-of-use assets, net124272
Long-term deposits and other assets316281
Available-for-sale securities, long-term1,1561,332
Equity investments5,0695,069
Intangible assets, net22,06432,088
Goodwill224,741224,741
Total assets411,152450,229
Current liabilities:  
Accounts payable11,98015,367
Accrued expenses and other current liabilities8,5689,782
Sales taxes payable5,4694,151
Warranty liability8,2158,312
Lease liabilities, operating, current portion2,9062,860
Lease liabilities, financing, current portion398158
Debt, current portion5,0341,814
Contingent consideration, current portion522,138
Total current liabilities42,62244,582
Contingent consideration, long-term3632,318
Lease liabilities, operating, long-term13,67714,962
Lease liabilities, financing, long-term1,250126
Debt, long-term20,93723,793
Deferred tax liabilities286250
Other long-term liabilities010
Total liabilities79,13586,041
Commitments and contingencies (Note 13)
Shareholders’ equity:  
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 150,000,000 shares authorized, 43,831,351 and 42,832,231 shares issued and outstanding, respectively, as of September 30, 2023 and December 31, 20224443
Additional paid-in capital632,593611,739
Accumulated other comprehensive loss, net of taxes(660)(679)
Accumulated deficit(299,960)(246,915)
Total shareholders’ equity332,017364,188
Total liabilities and shareholders’ equity$ 411,152$ 450,229
BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
 CEO
 WEBSITEwww.biolifesolutions.com
 EMPLOYEES466

BioLife Solutions Inc Frequently Asked Questions


What is the ticker symbol for BioLife Solutions Inc? What does BLFS stand for in stocks?

BLFS is the stock ticker symbol of BioLife Solutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioLife Solutions Inc (BLFS)?

As of Mon Dec 04 2023, market cap of BioLife Solutions Inc is 607.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart. The fair value of BioLife Solutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioLife Solutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLFS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioLife Solutions Inc a good stock to buy?

The fair value guage provides a quick view whether BLFS is over valued or under valued. Whether BioLife Solutions Inc is cheap or expensive depends on the assumptions which impact BioLife Solutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLFS.

What is BioLife Solutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 04 2023, BLFS's PE ratio (Price to Earnings) is -5.9 and Price to Sales (PS) ratio is 3.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLFS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioLife Solutions Inc's stock?

In the past 10 years, BioLife Solutions Inc has provided 0.055 (multiply by 100 for percentage) rate of return.